193 related articles for article (PubMed ID: 8602023)
1. Components of acellular pertussis vaccines.
Preston NW; Matthews RC
Lancet; 1996 Mar; 347(9003):764. PubMed ID: 8602023
[No Abstract] [Full Text] [Related]
2. Role of pertactin in pertussis vaccines: the jury is still out.
Desauziers E; Danve B; Decker MD; Veitch K
J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
[No Abstract] [Full Text] [Related]
3. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
4. Acellular pertussis vaccines: new vaccines for an old disease.
Poland GA
Lancet; 1996 Jan; 347(8996):209-10. PubMed ID: 8551875
[No Abstract] [Full Text] [Related]
5. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
6. Bordetella pertussis iron regulated proteins as potential vaccine components.
Alvarez Hayes J; Erben E; Lamberti Y; Principi G; Maschi F; Ayala M; Rodriguez ME
Vaccine; 2013 Aug; 31(35):3543-8. PubMed ID: 23731630
[TBL] [Abstract][Full Text] [Related]
7. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
[TBL] [Abstract][Full Text] [Related]
8. Immunoprophylaxis in pertussis.
Deb M
J Commun Dis; 1984 Mar; 16(1):54-60. PubMed ID: 12055788
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
10. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
12. Serological correlates of immunity to Bordetella pertussis.
Hewlett EL; Halperin SA
Vaccine; 1998 Dec; 16(20):1899-900. PubMed ID: 9796040
[No Abstract] [Full Text] [Related]
13. The advent of recombinant pertussis vaccines.
Burnette WN
Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
[No Abstract] [Full Text] [Related]
14. Japanese clinical trials with Takeda acellular pertussis vaccine.
Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
[TBL] [Abstract][Full Text] [Related]
15. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
16. Binding of murine antibodies against whole-cell pertussis vaccine or filamentous haemagglutinin by Bordetella pertussis from patients with whooping cough.
van den Berg BM; Beekhuizen H; Van Furth R; Mooi FR
Scand J Immunol; 2000 May; 51(5):530-2. PubMed ID: 10792847
[TBL] [Abstract][Full Text] [Related]
17. Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis.
Frühwirth M; Wolf H; Heininger H; Guggenbichler JP; Stehr E
Adv Exp Med Biol; 1995; 371B():777-83. PubMed ID: 7502896
[No Abstract] [Full Text] [Related]
18. [Immunobiological properties of Bordetella pertussis lipopolysaccharide in the acellular pertussis vaccine].
Zaĭtsev EM; Poddubikov AV; Britsina MV; Mertsalova NU; Ozeretskovskaia MN; Bazhanova IG; Plekhanova NG
Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):20-4. PubMed ID: 24738289
[TBL] [Abstract][Full Text] [Related]
19. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
